— Technology Description
Researchers at Washington University in St. Louis have developed a novel positron emission tomography (PET) radiopharmaceutical for myocardial perfusion imaging. Myocardial perfusion scintigraphy is widely employed in the evaluation of patients with heart disease. Several ag…
— T-020300 PET Radiotracers Capable of Crossing the Blood Brain Barrier and Detecting Reactive Oxygen Species
Technology Description
Reactive Oxygen Species (ROS) is known to contribute to the pathogenesis of neuropathological conditions such as Alzheimer’s disease and cancer. However, there&…
— T-019479 Tissue-penetrating PET radiotracer for non-invasive detection of ROS and inflammation.
Technology Description
18F-fluorodeoxyglucose (18F-FDG) has long been used for the diagnosis of neoplasms, and recently Alzheimer’s disease. However, 18F-FDG signals are often not correlated with…
— Technology Description
Researchers at Washington University in St. Louis have developed PET radiotracers to image amyloid beta (A-beta) at early stages of Alzheimer’s Disease (AD). For AD treatment to be effective, it may have to be administered during the preclinical stage. As such, there i…
— Background
8 million people per year are diagnosed with light-chain (AL) amyloidosis, a progressive disease than can quickly affect the kidney, heart, and nervous system if left untreated. The current method of diagnosis involves histological confirmation via biopsies of bone marrow, fat, and organ…
— Background
Frontotemporal Dementia (FTD) is the second most common form of non-Alzheimer’s dementia in the population under 65 years old. FTD represents approximately 20% of all dementias and onset normally appears in the mid to late 50s. Clinically FTD is characterized by a progressive neur…
| Name | # Summaries | Author |
|---|---|---|
| 15 | ||
| 13 | ||
| 15 | ||
| 26 | ||
| 14 | ||
| 14 |
Creating...
